Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Eli Lilly CEO: Alzheimer's drug trial shows slowed disease progression by 40-60% in early patients
01:01pm, Monday, 17'th Jul 2023
David Ricks, Eli Lilly chair and CEO, joins 'Squawk on the Street' to discuss the trial results for the company's Alzheimer's drug, how these results compare to those of Biogen and more.
Eli Lilly Says Alzheimer's Treatment Slows Cognitive Decline
11:00am, Monday, 17'th Jul 2023
A Phase 3 trial shows that Eli Lilly's investigational Alzheimer's treatment donanemab significantly slowed cognitive and functional decline in people in the early stages of the disease.
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
10:15am, Monday, 17'th Jul 2023
Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month.
Eli Lilly's Alzheimer's treatment shows promise in early stages of disease — but safety concerns remain
10:15am, Monday, 17'th Jul 2023
The Eli Lilly and Co. LLY, -0.47% investigational Alzheimer's treatment donanemab has shown particular promise in treating patients at younger ages and in the earliest stage of disease, according to n
Lilly drug slows Alzheimer's by 60% for mildly impaired patients, Alzheimer's group says
10:08am, Monday, 17'th Jul 2023
Eli Lilly's experimental drug donanemab slowed the progression of Alzheimer's by 60% for patients in the earliest stages of the brain-wasting disease, the Alzheimer's Association said in a press relea
Eli Lilly Stock: Bear Vs. Bull
08:45am, Monday, 17'th Jul 2023
Eli Lilly is adept at discovering and developing new medicines. The company's potential for innovation is bearing fruit.
Eli Lilly Buys Versanis to Boost Its Obesity Drug Portfolio
04:55pm, Friday, 14'th Jul 2023
Eli Lilly agreed to buy biopharma firm Versanis for up to $1.93 billion, boosting Lilly's reach into the obesity drug market.
Eli Lilly to expand in obesity drugs with $1.925 billion acquisition of Versanis Bio
01:51pm, Friday, 14'th Jul 2023
Shares of Eli Lilly & Co (NYSE: LLY) gained nearly 4.0% today after the pharmaceutical behemoth said it will buy Versanis Bio for up to $1.925 billion. Other financial details are yet to be disclosed
Why Eli Lilly Stock Is Rising Today
12:43pm, Friday, 14'th Jul 2023
Eli Lilly has agreed to buy privately owned Versanis Bio in a deal that could be worth up to $1.93 billion. Through this deal, Lilly will gain a novel mid-stage weight loss candidate known as bimagrum
Eli Lilly to acquire obesity drug maker Versanis for $1.9 billion
11:20am, Friday, 14'th Jul 2023
The deal is Eli Lilly's latest attempt to capitalize on the weight loss industry gold rush, which was sparked by demand for Novo Nordisk's Wegovy and Ozempic.
LLY Stock Alert: What to Know as Eli Lilly Acquires Versanis Bio
10:29am, Friday, 14'th Jul 2023
Eli Lilly (NYSE: LLY ) stock is a hot topic among traders on Friday after the company announced its acquisition of Versanis Bio . Versanis Bio is a clinical-stage biopharmaceutical company developing
Eli Lilly spends up to $1.93B to acquire obesity drug developer Versanis
09:56am, Friday, 14'th Jul 2023
Eli Lilly and Co (NYSE:LLY) announced on Friday that it will buy privately held drug developer Versanis for up to $1.93 billion, in a bid to improve its portfolio of obesity drugs. Under the terms of
Eli Lilly to Acquire Versanis Bio, Maker of Obesity Treatment
08:55am, Friday, 14'th Jul 2023
Versanis shareholders could receive as much as $1.925 billion in cash, which will consist of an upfront payment and additional payments if certain milestones are reached.
Lilly to buy Versanis for up to $1.93 bln to boost obesity drug portfolio
08:14am, Friday, 14'th Jul 2023
Eli Lilly and Co said on Friday it will acquire privately held drug developer Versanis for up to $1.93 billion, in a bid to boost its portfolio of obesity drugs.
Eli Lilly to acquire Versanis Bio, expanding obesity-treatment pipeline
08:14am, Friday, 14'th Jul 2023
Eli Lilly and Co. LLY, -1.34% will acquire Versanis Bio, a private clinical-stage biopharma company focused on new treatments for cardiometabolic diseases, the companies said in a release Friday. Vers
